Wednesday, March 22, 2023
HomeBusinessFDA approves GSK's anemia drug with safety warning — after batting back...

FDA approves GSK’s anemia drug with safety warning — after batting back similar drugs

With Novo Nordisk's obesity treatment Vegovy fully back in stock in December, sales are starting to rise, the Danish pharma reported Wednesday during its annual earnings call. Glucagon-like peptide 1 (GLP-1) Vigov's total scripts topped 37,000 weekly in mid-January, a hockey stick from year-end levels below 15,000 per week.

The new prescriptions come on top of the overall pace of sales of Novo obesity drug in 2022, though then-supply-constrained Vegovy was a part of that. Novo Nordisk's reported obesity segment sales accounted for DKK 10.7 billion ($1.58 billion) of Saxenda's total of DKK 16.9 billion ($2.49 billion), or about 63%.

See also  Berkshire Hathaway Slashed Stake in Taiwan Semi
- Advertisment -

Most Popular